| Michael Charles Deberardinis, MD | |
|
315 Martin Luther King Jr Way, Tacoma, WA 98405-4234 | |
| (253) 372-7102 | |
| Not Available |
| Full Name | Michael Charles Deberardinis |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Location | 315 Martin Luther King Jr Way, Tacoma, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073618419 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | MD00042829 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michael Charles Deberardinis, MD 315 Martin Luther King Jr Way, Tacoma, WA 98405-4234 Ph: (253) 372-7102 | Michael Charles Deberardinis, MD 315 Martin Luther King Jr Way, Tacoma, WA 98405-4234 Ph: (253) 372-7102 |
News Archive
A public health strategy that combines contact tracing and community-based screening with isolation and quarantine centers can substantially reduce infections, hospitalizations and deaths from COVID-19 while being cost-effective in low-and-middle-income countries like South Africa, a study by Massachusetts General Hospital has found.
City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.
Septic shock is caused by excessive and systemic reaction of the entire body against infectious agents, in most cases of bacterial origin. The number of deaths by septic shock in intensive care units is very high and is still increasing, despite numerous large scale clinical trials.
Pulse Health announces Revelar the first non-invasive device to help healthcare professionals and their patients measure aldehydes and help minimize free radical damage. Revelar is breakthrough breath technology that accurately detects and measures the presence of aldehydes, which are indicators of free radical damage in the body.
The U.S. government's fiscal predicament has many causes. But if you had to reduce them to one sentence, it might go like this: "Congress responds to the short-term demands of particular groups, not the long-term needs of the nation as a whole."
› Verified 5 days ago
Jesse Lee Mierzwiak, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 3124 S 19th St, Ste 320, Tacoma, WA 98405 Phone: 253-301-5100 | |
Dr. Scott Paul Cuda, M.D. Urology Medicare: Medicare Enrolled Practice Location: Madigan Army Medical Center 9040 Jackson Avenu, Tacoma, WA 98431 Phone: 253-968-2300 | |
Zachary Evan Panfili, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 209 Martin Luther King Jr Way, Tacoma, WA 98405 Phone: 253-596-3300 | |
Dr. William Matthew Dean, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 314 Martin Luther King Jr Way, Suite 103, Tacoma, WA 98405 Phone: 253-272-4013 Fax: 253-627-5367 | |
Carolyn Anne Salter, M.D. Urology Medicare: Medicare Enrolled Practice Location: 9040 Jackson Ave, Tacoma, WA 98431 Phone: 253-968-2252 | |
Timothy Brand, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 9040 Jackson Ave, Tacoma, WA 98431 Phone: 253-968-2300 |